Anixa Biosciences

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

We recently published a list of Top 8 AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Nano-X Imaging Ltd. (NASDAQ:NNOX) stands against other top AI news updates investors should not miss.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Aiforia and Techcyte announce strategic collaboration to advance AI-powered digital pathology Aiforia Technologies Plc, Press Release, March 21, 2025 at 09:00 a.m. EET Aiforia, a trusted provider of d

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million grant from the European Innovation Council (EIC) Accelerator to advance its AI and robotics synthesis automation technology.